1. Cersosimo F, Lonardi S, Bernardini G, Telfer B, Mandelli GE, Santucci A, et al. Tumor-associated macrophages in osteosarcoma: From mechanisms to therapy. Int J Mol Sci 2020; 21: 5207-5227.
2. Panez-Toro I, Munoz-Garcia J, Vargas-Franco JW, Renodon-Corniere A, Heymann MF, Lezot F, et al. Advances in osteosarcoma. Curr Osteoporos Rep 2023; 21:330-343.
3. Shoaib Z, Fan TM, Irudayaraj J. Osteosarcoma mechanobiology and therapeutic targets. Brit J Pharmacol 2022; 179: 201-217.
4. Su Q, Xu B, Tian Z, Gong Z. 1,3,5-triazines inhibit osteosarcoma and avert lung metastasis in a patient-derived orthotopic xenograft mouse model with favorable pharmacokinetics. Iran J Basic Med Sci 2022; 25: 295-301.
5. Meltzer PS, Helman LJ. New horizons in the treatment of osteosarcoma. New Engl J Med 2021; 385: 2066-2076.
6. Ding X, Lu D, Fan J. A natural product phillygenin suppresses osteosarcoma growth and metastasis by regulating the SHP-1/JAK2/STAT3 signaling. Biosci Biotech Bioch 2021; 85: 307-314.
7. Yuan R, Zhao W, Wang QQ, He J, Han S, Gao H, et al. Cucurbitacin B inhibits non-small cell lung cancer in vivo and in vitro by triggering TLR4/NLRP3/GSDMD-dependent pyroptosis. Pharmacol Res 2021; 170: 105748-105763.
8. Dai S, Wang C, Zhao X, Ma C, Fu K, Liu Y, et al. Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics. Pharmacol Res 2023;187: 106587-106607.
9. Wei J, Chen X, Li Y, Li R, Bao K, Liao L, et al. Cucurbitacin B-induced G2/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78-FOXM1-KIF20A pathway. Acta Pharm Sin B 2022; 12: 3861-3876.
10. Yuan R, Fan Q, Liang X, Han S, He J, Wang QQ, et al. Cucurbitacin B inhibits TGF-beta1-induced epithelial-mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K/Akt/mTOR pathways. Chin Med 2022; 17: 24-40.
11. Zhang H, Zhao B, Wei H, Zeng H, Sheng D, Zhang Y. Cucurbitacin B controls M2 macrophage polarization to suppresses metastasis via targeting JAK-2/STAT3 signalling pathway in colorectal cancer. J Ethnopharmacol 2022; 287: 114915.
12. Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, et al. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009; 69: 5876-5884.
13. Lee DH, Thoennissen NH, Goff C, Iwanski GB, Forscher C, Doan NB, et al. Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett 2011; 306: 161-170.
14. Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen 2017; 58: 235-263.
15. Nassiri-Asl M, Ghorbani A, Salehisar S, Asadpour E, Sadeghnia HR. Effect of rutin on oxidative DNA damage in PC12 neurons cultured in nutrients deprivation condition. Iran J Basic Med Sci 2020; 23: 390-395.
16. Sadoughi F, Maleki DP, Asemi Z, Yousefi B. DNA damage response and repair in osteosarcoma: Defects, regulation and therapeutic implications. DNA Repair 2021; 102: 103105.
17. Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer 2022; 3: 1452-1463.
18. Chen C, Xu P. Cellular functions of cGAS-STING signaling. Trends Cell Biol 2023; 33: 630-648.
19. Hopfner KP, Hornung V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat Rev Mol Cell Bio 2020; 21: 501-521.
20. Wu Y, Chen W, Xu ZP, Gu W. PD-L1 Distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol 2019; 10: 2022-2037.
21. Oghalaie A, Mahboudi F, Rahimi-Jamnani F, Piri-Gavgani S, Kazemi-Lomedasht F, Hassanzadeh Eskafi A, et al. Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate. Iran J Basic Med Sci 2022; 25: 313-319.
22. Zhou Y, Yang Q, Dong Y, Ji T, Zhang B, Yang C, et al. First-in-maintenance therapy for localized high-grade osteosarcoma: An open-label phase I/II trial of the anti-PD-L1 antibody ZKAB001. Clin Cancer Res 2023; 29: 764-774.
23. Tang Z, Zhao L, Yang Z, Liu Z, Gu J, Bai B, et al. Mechanisms of oxidative stress, apoptosis, and autophagy involved in graphene oxide nanomaterial anti-osteosarcoma effect. Int J Nanomed 2018; 13: 2907-2919.
24. Jiang H, Zhao X, Zang J, Wang R, Gao J, Chen J, et al. Establishment of a prognostic risk model for osteosarcoma and mechanistic investigation. Front Pharmacol 2024; 15: 1399625-1399640.
25. Chittasupho C, Samee W, Na Takuathung M, Okonogi S, Nimkulrat S, Athikomkulchai S. Clerodendrum chinense stem extract and nanoparticles: Effects on proliferation, colony formation, apoptosis induction, cell cycle arrest, and mitochondrial membrane potential in human breast adenocarcinoma breast cancer cells. Int J Mol Sci 2024; 25: 978-1003.
26. Ma Q, Li X, Wang H, Xu S, Que Y, He P, et al. HOXB5 promotes the progression and metastasis of osteosarcoma cells by activating the JAK2/STAT3 signalling pathway. Heliyon 2024; 10: e30445-459.
27. Li J, Jiang W, Shan W, Luo A, Qu G, Zhang J, et al. The synergistic anticancer effect of CBD and DOX in osteosarcoma. Clin Transl Oncol 2023; 25: 2408-2418.
28. Lu Y, Liu Y, Yang C. Evaluating in vitro DNA damage using comet assay. J Vis Exp 2017; 128: 56450-56456.
29. Carlsson MJ, Vollmer AS, Demuth P, Heylmann D, Reich D, Quarz C, et al. p53 triggers mitochondrial apoptosis following DNA damage-dependent replication stress by the hepatotoxin methyleugenol. Cell Death Dis 2022; 13: 1009-1024.
30. Kwon J, Bakhoum SF. The cytosolic dna-sensing cGAS-STING pathway in cancer. Cancer Discov 2020; 10: 26-39.
31. Goldstein M, Kastan MB. The DNA damage response: Implications for tumor responses to radiation and chemotherapy. Annu Rev Med 2015; 66: 129-143.
32. Reislander T, Groelly FJ, Tarsounas M. DNA damage and cancer immunotherapy: A STING in the tale. Mol Cell 2020; 80: 21-28.
33. Yang K, Han W, Jiang X, Piffko A, Bugno J, Han C, et al. Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration. Nat Nanotechnol 2022; 17: 1322-1331.
34. Fang L, Tian W, Zhang C, Wang X, Li W, Zhang Q, et al. Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma. Pharmacol Res 2023; 189: 106701-106714.
35. Ding L, Qian J, Yu X, Wu Q, Mao J, Liu X, et al. Blocking MARCO(+) tumor-associated macrophages improves anti-PD-L1 therapy of hepatocellular carcinoma by promoting the activation of STING-IFN type I pathway. Cancer Lett 2024; 582: 216568.